News|Articles|November 12, 2025
Operationalizing DSCSA Compliance in the Warehouse
Author(s) Tecsys
Key Takeaways
- Personalized treatment strategies have advanced lung cancer brain metastases management, integrating targeted therapies and immunotherapies for improved outcomes.
- Stereotactic radiosurgery and whole-brain radiation therapy are evolving with new systemic therapies, maintaining their importance in treatment.
The Drug Supply Chain Security Act (DSCSA) serialization mandate is now in full effect. Every pharmaceutical distributor and 3PL must trace serialized product at the unit level and stay in sync with trading partners in real time. There are multiple ways to meet the minimum requirements — but only one approach delivers full compliance without operational disruption. Tecsys provides that solution: the most complete, warehouse-native serialization capability, built directly into core workflows so compliance happens automatically as you work.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
2
Henlius Enters Global Exclusive License Agreement with U-mab Biopharma for Best-in-Class Potential Anti-IL-1RAP mAb
3
GSK Enters $2.2 Billion Definitive Agreement to Acquire RAPT Therapeutics
4
Atkins Announces Partnership with Reality TV Star Heather Gay to Address GLP-1 User’s Mindsets
5